Long-term Aspirin use Reduces the Incidence of Digestive Cancers by up to 47%, Study Presented at UEG Week Reveals

Food and Healthcare Press Releases Tuesday October 31, 2017 08:00
BARCELONA, Spain--31 Oct--PRNewswire/InfoQuest
The long-term use of aspirin has been shown to significantly reduce the incidence of digestive cancers, new research presented today at the 25th UEG Week have found[1].

In a study involving over 600,000 people, researchers compared patients who were prescribed aspirin over a long period (for at least six months, average duration of aspirin prescribed was 7.7 years) with non-aspirin users and assessed the incidences of a number of cancers. Those prescribed with aspirin showed a 47% reduction in liver and oesophageal cancer incidence, a 38% reduction in gastric cancer incidence, a 34% reduction in pancreatic cancer incidence and a 24% reduction in colorectal cancer incidence.

Digestive cancers account for almost a quarter of cancer cases in Europe[2]. Colorectal, gastric and pancreatic cancer are within the top five cancer killers throughout the continent, with digestive cancers representing 30.1% of cancer deaths.

Aspirin is used across the globe to treat a number of health conditions, ranging from short-term pain relief to long-term prescriptions. Whilst the use of aspirin is subject to continued debate within the medical community, a recent study found that patients who stopped taking aspirin were 37% more likely to have an adverse cardiovascular event, such as a heart attack or stroke, than those who continued with their prescription[3].

Reduction in incidence of cancer by
Cancer Site                   aspirin user
(compared with non-user)
Liver                         47%
Oesophageal                       47%
Gastric                         38%
Pancreatic                       34%
Colorectal                       24%
Table 1 - Reduction in incidence of digestive cancer

The effect of long-term use of aspirin on cancer incidence was also examined for cancers outside of the digestive system. Here, a significant reduction was shown for some (leukaemia, lung and prostate) but not all (breast, bladder, kidney and multiple myeloma) cancers.

Lead researcher, Professor Kelvin Tsoi from the Chinese University of Hong Kong, presented the study today at the 25th UEG Week in Barcelona. "The findings demonstrate that the long-term use of aspirin can reduce the risk of developing many major cancers," commented Professor Tsoi. "What should be noted is the significance of the results for cancers within the digestive tract, where the reductions in cancer incidence were all very substantial, especially for liver and oesophageal cancer."

References:

1. Tsoi, K. et al. Long-term use of aspirin is more effective to reduce the incidences of gastrointestinal cancers than non-gastrointestinal cancers: A 10-year population based study in Hong Kong. Presented at UEG Week Barcelona 2017.

2. GLOBOCAN, IARC (2012). Section of Cancer Surveillance.
3. Stopping aspirin treatment raises cardiovascular risk by over a third (2017). Available at: https://www.medicalnewstoday.com/articles/319541.php
Source: United European Gastroenterology (UEG)

Latest Press Release

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

- FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of first clinical data in BTC - BTC is a group of rare, aggressive...

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

- Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological profiles - Evaluation to include...

Vitality-linked Insurers to Get 100 million People 20% More Active by 2025

Building on the results of the largest behaviour change study on physical activity, Vitality and its global network of insurers have collectively committed to improving the health of millions over the next seven years. This is in line with the World...

World Congress of Cardiology Cardiovascular Health 2018 Opens in Dubai

- Professor David Wood, President of the World Heart Federation, welcomes more than 5000 cardiologists, doctors, nurses, and health and policy experts from around the world to Dubai for WCC 2018 at a time when the opportunities for a sustainable impact...

Data Presented at 2nd Healthy Lung Summit 2018 to Demonstrate Impact of AstraZeneca#s Healthy Lung Partnership Programme

Deepening commitment to drive improvements for patients with respiratory disease across Asia, AstraZeneca with Business Sweden, The Swedish Trade & Invest Council in Taiwan, hosts the second Healthy Lung Summit, ahead of the 2018 Asia Pacific Society...

Related Topics